摘要
目的 探讨利福昔明对肠易激综合征（irritable bowel syndrome,IBS）患者的临床疗效.方法 计算机检索中国生物医学文献数据库（CBM）（2001年1月-2013年10月）及外文数据库PubMed（2001年1月-2013年10月）,收集利福昔明治疗IBS的所有随机对照试验（RCT）,并对所有资料进行Meta分析.结果 共纳入5个RCT,2 124例患者.Meta分析结果显示：利福昔明实验组总体疗效优于对照组,能够有效缓解IBS患者全部症状（OR=1.61,95％CI：1.35 ～1.93）,且无明显异质性（P=0.32,I2=14％）.对于次要结局指标腹胀缓解,仅3个RCT收集该有效数据,表明利福昔明实验组相对于对照组能有效缓解患者腹胀（OR=1.62,95％CI：1.35～1.96）,且无明显异质性（P=0.39,I2=1％）.发生药物不良反应较少,利福昔明实验组和对照组副反应发生率相比,差异无统计学意义（P＞0.05）.结论 利福昔明在提高IBS的总体疗效及缓解腹胀症状等方面疗效显著,且副作用发生率低.
Objective To investigate the clinical efficacy of Rifaximin in patients with irritable bowel syndrome （IBS）. Methods Chinese Biomedical Literature Database （CBM） and foreign language database PubMed were searched from Jan. 2001 to Oct. 2013. All domestic randomized controlled trials （RCT） on Rifaximin in treating IBS were collected, and the Meta-analysis was performed with RevmanS. 1. Results A total of 5 RCTs involving 2 124 pa- tients were included. Meta-analysis found Rifaximin to be more effective than placebo for symptom improvement （OR = 1.61, 95% CI： 1.35 - 1.93 ） , with no significant heterogeneity （P = 0.32, I= 14% ）. For the key secondary outcome of bleating datas were available for three studies. Rifaximin was significantly more likely to alleviate bloating than place- bo （OR = 1.62, 95% CI： 1.35 - 1.96） , with no significant heterogeneity （P =0.39, I= 1% ）. Side effects were rare and there was no significantly difference （P 〉 0.05）. Conclusion Rifaximin is more effective than placebo for relieve symptoms and bloating in IBS patients, and the incidence of side effects is low.
出处
《胃肠病学和肝病学杂志》
CAS
2015年第3期287-290,共4页
Chinese Journal of Gastroenterology and Hepatology
基金
福建省自然科学基金(2013J01394)
作者简介
第一作者简介：刘妍，研究方向：胃肠动力学。E-mail：514461566@qq.com
通讯作者：张鸣青，主任医师，研究方向：胃肠动力学。E-mail：zmqing8084@sina．com
